-
1Academic Journal
Συγγραφείς: A. V. Polynovsky, D. V. Kuzmichev, A. A. Tryakin, M. V. Chernykh, O. A. Kuznetsova, I. A. Karasev, D. V. Aleksantsev, A. M. Karachun, E. V. Tkachenko, E. I. Turyaeva, D. V. Samsonov, I. M. Gridasov, S. E. Prokofiev, Z. Z. Mamedli, А. В. Полыновский, Д. В. Кузьмичев, А. А. Трякин, М. В. Черных, О. А. Кузнецова, И. А. Карасев, Д. В. Алексанцев, А. М. Карачун, Е. В. Ткаченко, Е. И. Тюряева, Д. В. Самсонов, И. М. Гридасов, С. Е. Прокофьев, З. З. Мамедли
Πηγή: Surgery and Oncology; Том 15, № 1 (2025); 18-27 ; Хирургия и онкология; Том 15, № 1 (2025); 18-27 ; 2949-5857
Θεματικοί όροι: индукционная/консолидирующая химиотерапия, total neoadjuvant chemotherapy, chemoradiotherapy, induction/consolidation chemotherapy, тотальная неоадъювантная химиотерапия, химиолучевая терапия
Περιγραφή αρχείου: application/pdf
Relation: https://www.onco-surgery.info/jour/article/view/777/490; Злокачественные новообразования в России в 2018 году (заболеваемость и смертность). Под ред. А.Д. Каприна, В.В. Старинского, Г.В. Петровой. М.: МНИОИ им. П.А. Герцена – филиал ФГБУ «НМИЦ радиологии» Минздрава России, 2019. 250 с.; Breugom A.J., van den Broek C.B.M., van Gijn W. et al. The value of adjuvant chemotherapy in rectal cancer patients after preoperative radiotherapy or chemotherapy followed by TMEsurgery: the PROCTOR/SCRIPT study. Eur J Cancer 2013;49:1.; Cionini L., Sainato A., de Paoli A. et al. Final results of randomized trial on adjuvant chemotherapy after preoperative chemoradiation in rectal cancer. Radiother Oncol 2010;96:113–4.; Glynne-Jones R., Chau I. Neoadjuvant therapy before surgical treatment. EJC Suppl 2013;11(2):45–59.; Rödel C., Liersch T., Becker H. et al. Preoperative chemoradiotherapy and postoperative chemotherapy with fluorouracil and oxaliplatin versus fluorouracil alone in locally advanced rectal cancer: initial results of the German CAO/ARO/ AIO-04 randomised phase 3 trial. Lancet Oncol 2012;13:679–87.; Ludmir E.B., Palta M., Willett C.G. et al. Total neoadjuvant therapy for rectal cancer: an emerging option. Cancer 2017;123:1497–506. DOI:10.1002/cncr.30600; Franke A.J., Parekh H., Starr J.S. et al. Total neoadjuvant therapy: a shifting paradigm in locally advanced rectal cancer management. Clin Colorectal Cancer 2018;17:1–12.; Bahadoer R.R., Dijkstra E.A., van Etten B. et al. Short-course radiotherapy followed by chemotherapy before total mesorectal excision (TME) versus preoperative chemoradiotherapy, TME, and optional adjuvant chemotherapy in locally advanced rectal cancer (RAPIDO): a randomised, open-label, phase 3 trial. Lancet Oncol 2020;22(1):29–42. DOI:10.1016/S1470-2045(20)30555-6; Conroy T., Bosset J.-F., Etienne P-L. et al. Neoadjuvant chemotherapy with FOLFIRINOX and preoperative chemoradiotherapy for patients with locally advanced rectal cancer (UNICANCER-PRODIGE 23): a multicentre, randomised, openlabel, phase 3 trial. Lancet Oncol 2021;22(5):702–15. DOI:10.1016/S1470-2045(21)00079-6; Jin J., Tang Y., Hu C. et al. Multicenter, randomized, phase III trial of short-term radiotherapy plus chemotherapy versus long-term chemoradiotherapy in locally advanced rectal cancer (STELLAR). J Clin Oncol 2022;40(15):1681–92. DOI:10.1200/JCO.21.01667; Liao C.-K., Kuo Y.-T., Lin Y.-C. et. al. Neoadjuvant short-course radiotherapy followed by consolidation chemotherapy before surgery for treating locally advanced rectal cancer: a systematic review and meta-analysis. Curr Oncol 2022;29(5):3708–27. DOI:10.3390/curroncol29050297; Gabbani M., Giorgi C., Napoli G. et al. Outcomes of locally advanced rectal cancer patients treated with total neoadjuvant treatment: a meta-anaysis of randomized controlled trials. Clin Colorectal Cancer 2022;21(4):297–308. DOI:10.1016/j.clcc.2022.07.005; Petrelli F., Trevisan F., Cabiddu M. et al. Total neoadjuvant therapy in rectal cancer: a systematic review and meta-analysis of treatment outcomes. Ann Surg 2020;271(3):440–8. DOI:10.1097/SLA.0000000000003471; Liu S., Jiang T., Xiao L. et al. Total neoadjuvant therapy versus standard neoadjuvant chemoradiotherapy for locally advanced rectal cancer: a systematic review and meta-analysis. Oncologist 2021;26(9):e1555–e6. DOI:10.1002/onco.13824; Maas M., Nelemans P.J., Valentini V. et al. Long-term outcome in patients with a pathological complete response after chemoradiation for rectal cancer: a pooled analysis of individual patient data. Lancet Oncol 2010;11:835–44.; Habr-Gama A., Perez R.O., Nadalin W. et al. Operative versus nonoperative treatment for stage 0 distal rectal cancer following chemoradiation therapy: long-term results. Ann Surg 2004;240(4):711–7. DOI:10.1097/01.sla.0000141194.27992.32; Romesser P.B., Park B.K., Nemirovsky D. et al. Organ preservation and total neoadjuvant therapy for rectal cancer: investigating long course chemoradiation versus short-course radiation therapy. J Clin Oncol 2023;41(4):10. DOI:10.1200/JCO.2023.41.4_suppl.10; Cionini L., Sainato A., de Paoli A. et al. Final results of randomized trial on adjuvant chemotherapy after preoperative chemoradiation in rectal cancer. Radiother Oncol 2010;96:S113–4.
-
2Academic Journal
Συγγραφείς: А. В. Полыновский, З. З. Мамедли, Д. В. Кузьмичев, А. А. Анискин, Д. В. Алексанцев
Πηγή: Malignant tumours; Том 12, № 3s1 (2022); 69-75 ; Злокачественные опухоли; Том 12, № 3s1 (2022); 69-75 ; 2587-6813 ; 2224-5057
Θεματικοί όροι: индукционная / консолидирующая химиотерапия, тотальная неоадъювантная химиотерапия, химиолучевая терапия
Περιγραφή αρχείου: application/pdf
Relation: https://www.malignanttumors.org/jour/article/view/1003/700; Kaprin A. D. Malignant neoplasms in Russia in 2018 (morbidity and mortality) // P. Hertsen Moscow Oncology Research Institute, 2019–249 p.; Breugom AJ, van den Broek CBM, van Gijn W, et al. The value of adjuvant chemotherapy in rectal cancer patients after preoperative radiotherapy or chemotherapy followed by TME-surgery : the PROCTOR / SCRIPT study // Eur J Cancer. 2013. 49, S1.; Cionini L, Sainato A, De Paoli A et al. Final results of randomized trial on adjuvant chemotherapy after preoperative chemoradiation in rectal cancer. // Radiother Oncol. 2010. 96, S113-S114.; Glynne-Jones R, Chau I. Neoadjuvant therapy before surgical treatment. // EJC Suppl. 2013 EJC Suppl. 2013. 11 (2), 45–59.; Rödel C, Liersch T, Becker H, et al. Preoperative chemoradiotherapy and postoperative chemotherapy with fluorouracil and oxaliplatin versus fluorouracil alone in locally advanced rectal cancer : initial results of the German CAO / ARO / AIO-04 randomised phase 3 trial. Lancet Oncol. 2012; 13 : 679–687.].; Ludmir EB, Palta M, Willett CG, et al. Total neoadjuvant therapy for rectal cancer : An emerging option. Cancer. 2017; 123 : 1497–1506. doi:10.1002/cncr.30600.; Franke AJ, Parekh H, Starr JS, et al. Total neoadjuvant therapy : a shifting paradigm in locally advanced rectal cancer management. Clin Colorectal Cancer. 2018; 17 : 1–12.; Gabbani M., Giorgi C., Napoli G. et al. Outcomes of Locally Advanced Rectal Cancer Patients Treated with Total Neoadjuvant Treatment : A Meta-Anaysis of Randomized Controlled Trials. Clinical Colorectal Cancer, Vol. 000, No. xxx, 1–12 ©2022.; Fernández-Martos C., Pericay C., Aparicio J., et al. Phase II, randomized study of concomitant chemoradiotherapy followed by surgery and adjuvant capecitabine plus oxaliplatin (CAPOX) compared with induction CAPOX followed by concomitant chemoradiotherapy and surgery in magnetic resonance imaging-defi ned, locally advanced rectal cancer : Grupo cancer de recto 3 study. J Clin Oncol. 2010; 28 (5) : 859–65.; Fokas E., Phil D., Allgauer M. et al. Randomized Phase II Trial of Chemoradiotherapy Plus Induction or Consolidation Chemotherapy as Total Neoadjuvant Therapy for Locally Advanced Rectal Cancer : CAO / ARO / AIO-12. Journal of Clinical Oncology 2019; 37. DOI https://doi.org/10.1200/JCO.19.00308.; Gao Y. H., Lin J. Z., An X. et al. Neoadjuvant Sandwich Treatment with Oxaliplatin and Capecitabine Administered Prior to, Concurrently with, and Following Radiation Therapy in Locally Advanced Rectal Cancer : a Prospective Phase 2 Trial // Int. J. Radiat. Oncol. Biol. Phys. 2014. V. 90, No. 5. P. 1153–1160.; Marco MR, Zhou L, Patil S, et al : Consolidation mFOLFOX6 chemotherapy after chemoradiotherapy improves survival in patients with locally advanced rectal cancer : Final results of a multicenter phase II trial. Dis Colon Rectum 61 : 1146–1155, 2018.; Maas M, Nelemans PJ, Valentini V, et al : Long-term outcome in patients with a pathological complete response after chemoradiation for rectal cancer : A pooled analysis of individual patient data. Lancet Oncol 11 : 835–844, 2010.; https://www.malignanttumors.org/jour/article/view/1003
-
3Academic Journal
Συγγραφείς: A. A. Aniskin, D. V. Kuzmichev, Z. Z. Mamedli, A. V. Polynovskiy, А. А. Анискин, Д. В. Кузьмичев, З. З. Мамедли, А. В. Полыновский
Πηγή: Surgery and Oncology; Том 11, № 2 (2021); 29-35 ; Хирургия и онкология; Том 11, № 2 (2021); 29-35 ; 2949-5857
Θεματικοί όροι: безрецидивная выживаемость, comprehensive treatment, consolidation chemotherapy, induction chemotherapy, relapse-free survival, комплексное лечение, консолидирующая химиотерапия, индукционная химиотерапия
Περιγραφή αρχείου: application/pdf
Relation: https://www.onco-surgery.info/jour/article/view/507/366; NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®): Cancer. Available at: https://www.nccn.org/guidelines/guidelinesdetail?category=1&id=1461.; Peeters K.C., Marijnen C.A., Nagtegaal I.D. et al. The TME trial after a median followup of 6 years: increased local control but no survival benefit in irradiated patients with resectable rectal carcinoma. Ann Surg 2007;246(5):693–701.; Chen C., Sun P., Rong J. et al. Short course radiation in the treatment of localized rectal cancer: A systematic review and meta-analysis. Sci Rep 2015;5:10953.; Sineshaw H.M., Jemal A., Thomas C.R., Mitin T. Changes in treatment patterns for patients with locally advanced rectal cancer in the United States over the past decade: An analysis from the National Cancer Data Base. Cancer 2016;122(13):1996–2003.; Yanwu S., Zhekun H., Yiyi Zh. et al. Is early initiation of adjuvant chemotherapy beneficial for locally advanced rectal cancer following neoadjuvant chemoradiotherapy and radical surgery? World J Surg 2020;44(9):3149–57. DOI:10.1007/s00268-020-05573-4.; Rödel C., Liersch T., Becker H. et al. Preoperative chemo-radiotherapy and postoperative chemotherapy with fluorouracil and oxaliplatin versus fluorouracil alone in locally advanced rectal cancer: initial results of the German CAO/ARO/AIO-04 randomised phase 3 trial. Lancet Oncol 2012;13(7):679–87.; Bosset J.F., Calais G., Mineur L. et al. Fluorouracil-based adjuvant chemotherapy after preoperative chemoradiotherapy in rectal cancer: long-term results of the EORTC 22921 randomised study. Lancet Oncol 2014;15(2):184–90. DOI:10.1016/S1470-2045(13)70599-0.; Shu-Biao Y., Yi-Kan Ch., Lin Zh. et al. Association of mismatch repair status with survival and response to neoadjuvant chemo(radio)therapy in rectal cancer. NPJ Precis Oncol 2020;4:26. DOI:10.1038/s41698-020-00132-5.; Акилджонов Ф.Р., Бузиашвили Ю.И., Стилиди И.С. и др. Сердечные биомаркеры у пациентов после химиотерапии. Медицинский алфавит 2021;19(471):49–53.; Gérard J.P., Azria D., Gourgou-Bourgade S. et al. Comparison of two neoadjuvant chemoradiotherapy regimens for locally advanced rectal cancer: results of the phase III trial ACCORD 12/0405-Prodige 2. J Clin Oncol2010;28(10):1638–44.; Aschele C., Cionini L., Lonardi S. et al. Primary tumor response to preoperative chemoradiation with or without oxaliplatin in locally advanced rectal cancer: pathologic results ofthe STAR-01 randomized phase III trial. J Clin Oncol 2011;29(20):2773–80.; Артамонова Е.В. Современная стратегия лечения метастатического колоректального рака – ключ к увеличению продолжительности жизни пациентов с метастатическим колоректальным раком без мутаций в генах RAS. Медицинский алфавит 2021;19(471):54–63. DOI:10.33667/2078-5631-2021-19-54-63.; Glynne-Jones R., Mawdsley S., Harrison M. Cetuximab and chemoradiation for rectal cancer – is the water getting muddy? Acta Oncol 2010;49(3):278–86. DOI:10.3109/02841860903536010.; Hu Y.H., Wei J.W., Chang H. et al. The high pCR rate of sandwich neoadjuvant treatment in locally advanced rectal cancer may translate into a better long-term survival benefit: 5-year outcome of a Phase II clinical trial. Cancer Manag Res 2018;10: 4363–9. DOI:10.2147/CMAR.S168573.; Golo D., But-Hadzic J., Anderluh F. et al. Induction chemotherapy, chemoradiotherapy and consolidation chemotherapy in preoperative treatment of rectal cancer – long-term results of Phase II OIGIT-01 Trial. Radiol Oncol 2018;52(3):267–74. DOI:10.2478/raon-2018-0028.; Xiao J., Chen Z., Li W. et al. Sandwichlike neoadjuvant therapy with bevacizumab for locally advanced rectal cancer: a phase II trial. Cancer Chemother Pharmacol 2015;76(1):21–7.; Кит О.И., Геворкян Ю.А., Солдаткина Н.В. и др. Современные прогностические факторы при колоректальном раке. Колопроктология 2021;2(76):42–9.; Williams G.T., Quirke P., Shepherd N.A. Dataset for Colorectal Cancer. 2nd edn, 2007. Available at: http://www.rcpath.org/resources/worddocs/G049ColorectalDatasetAppendixC-Sep07.doc.; Chand M., Bhangu A., Wotherspoon A. et al. EMVI-positive stage II rectal cancer has similar clinical outcomes as stage III disease following pre-operative chemoradiotherapy. Ann Oncol 2014;25(4):858–63. DOI:10.1093/annonc/mdu029.
-
4Academic Journal
Συγγραφείς: A. A. Kachmazov, L. V. Bolotina, A. L. Kornietskaya, Yu. B. Karagodina, I. V. Droshneva, A. A. Fedenko, А. А. Качмазов, Л. В. Болотина, А. Л. Корниецкая, Ю. Б. Карагодина, И. В. Дрошнева, А. А. Феденко
Πηγή: Surgery and Oncology; Том 10, № 3-4 (2020); 73-83 ; Хирургия и онкология; Том 10, № 3-4 (2020); 73-83 ; 2949-5857
Θεματικοί όροι: консолидирующая химиотерапия, locally advanced cancer, watch-and-wait, neoadjuvant therapy, consolidation chemotherapy, местно-распространенный рак, органосохраняющее лечение, неоадъювантная терапия
Περιγραφή αρχείου: application/pdf
Relation: https://www.onco-surgery.info/jour/article/view/487/354; Практические рекомендации по лекарственному лечению злокачественных опухолей. Под ред. В.М. Моисеенко. Российское общество клинической онкологии, 2019. Доступно по: https://rosoncoweb.ru/standarts/RUSSCO/2019/2019-22.pdf.; NCCN Clinical Practice Guidelines in Oncology – Rectal Cancer. Version 4.2020. National Comprehensive Cancer Network.; Glynne-Jones R., Wyrwicz L., Tiret E. et al. Rectal cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol Off J Eur Soc Med Oncol 2017;28(Suppl 4):iv22–iv40. DOI:10.1093/annonc/mdx224. Available at: https://www.annalsofoncology.org/article/S0923-7534(19)42152-2/abstract.; Клинические рекомендации по лечению онкологических заболеваний. Под ред. А.Д. Каприна. Ассоциация онкологов России, 2020. Доступно по: https://oncology-association.ru/files/clinical-guidelines-2020/rak_prjamoj_kishki.pdf.; MacFarlane J.K., Ryall R.D.H., Heald R.J. Mesorectal excision for rectal cancer. The Lancet 1993;341(8843): 457–60. Available at: https://www.sciencedirect.com/science/article/abs/pii/014067369390207W.; Lambregts D.M.J., Beets-Tan R.G.H. Optimal imaging staging of rectal cancer. Eur J Cancer Suppl 2013;11(2):38–44. Available at: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4041181/.; Roh M.S., Colangelo L., O’Connell M.J. et al. Preoperative multimodality therapy improves disease-free survival in patients with carcinoma of the rectum: NSABP R-03. J Clin Oncol Off J Am Soc Clin Oncol 2009;27(31):5124–30. Available at: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2773471/.; Gérard J.-P., Conroy T., Bonnetain F. et al. Preoperative radiotherapy with or without concurrent fluorouracil and leucovorin in T3–4 rectal cancers: results of FFCD 9203. J Clin Oncol Off J Am Soc Clin Oncol 2006;24(28):4620–5. Available at: http://estro.dokeos.com/courses/ESTRORECTAL/document/recommended_articles/24-06_JCO_Gerard_FFCD.pdf.; Valentini V., Bonnetain F., Gambacorta M. et al. Nomograms for predicting local recurrence, distant metastases, and overall survival for patients with locally advanced rectal cancer on the basis of European randomized clinical trials. J Clin Oncol Off J Am Soc Clin Oncol 2011;29(23):3163–72. Available at: https://www.researchgate.net/profile/Marek_Bebenek/publication/51483716_Nomograms_for_Predicting_Local_Recurrence_Distant_Metastases_and_Overall_Survival_for_Patients_With_Locally_Advanced_Rectal_Cancer_on_the_Basis_of_European_Randomized_Clinical_Trials/links/0a85e53224d63d60e0000000/Nomograms-for-Predicting-Local-Recurrence-Distant-Metastases-and-Overall-Survival-for-Patients-With-Locally-Advanced-Rectal-Cancer-on-the-Basis-of-European-Randomized-Clinical-Trials.pdf.; Bujko K., Nowacki M., Nasierowska‐ Guttmejer A. et al. Long-term results of a randomized trial comparing preoperative short-course radiotherapy with preoperative conventionally fractionated chemoradiation for rectal cancer. Br J Surg 2006;93(10):1215–23. Available at: https://www.ingentaconnect.com/content/jws/bjs/2006/00000093/00000010/art00007.; Ngan S.Y., Bryan B., Goldstein D. et al. Randomized trial of short-course radiotherapy versus long-course chemoradiation comparing rates of local recurrence in patients with T3 rectal cancer: Trans-Tasman Radiation Oncology Group trial 01.04. J Clin Oncol Off J Am Soc Clin Oncol 2012;30(31): 3827–33. Available at: https://www.researchgate.net/profile/Stephen_Ackland/publication/231176339_Randomized_Trial_of_Short-Course_Radiotherapy_Versus_Long-Course_Chemoradiation_Comparing_Rates_of_Local_Recurrence_in_Patients_With_T3_Rectal_Cancer_Trans-Tasman_Radiation_Oncology_Group_Trial_0104/links/57fcdef008aed4ab46fe6730/Randomized-Trial-of-Short-Course-Radiotherapy-Versus-Long-Course-Chemoradiation-Comparing-Rates-of-Local-Recurrence-in-Patients-With-T3-Rectal-Cancer-Trans-Tasman-Radiation-Oncology-Group-Trial-0104.pdf.; Francois Y., Nemoz C., Baullieux J. et al. Influence of the interval between preopera tive radiation therapy and surgery on down-staging and on the rate of sphincter-sparing surgery for rectal cancer: the Lyon R90-01 randomized trial. J Clin Oncol Off J Am Soc Clin Oncol 1999;17(8):2396. Available at: http://citeseerx.ist.psu.edu/viewdoc/download?doi=10.1.1.1010.4888&rep=rep1&type=pdf.; Raymond E., Chaney S., Taamma A., Cvitkovic E. et al. Oxaliplatin: a review of preclinical and clinical studies. Ann Oncol Off J Eur Soc Med Oncol 1998;9(10):1053–71. Available at: https://www.sciencedirect.com/science/article/pii/S0923753419482045.; Goldberg R.M., Gill S. Recent phase III trials of fluorouracil, irinotecan, and oxaliplatin as chemotherapy for metastatic colorectal cancer. Cancer Chemother Pharmacol 2004;54(Suppl 1):S57–64. Available at: https://link.springer.com/article/10.1007/s00280-004-0888-9.; Goldberg R.M., Sargent D., Morton R. et al. A randomized controlled trial of fluorouracil plus leucovorin, irinotecan, and oxaliplatin combinations in patients with previously untreated metastatic colorectal cancer. J Clin Oncol 2004;22(1):23–30. Available at: http://www.hayaobio.net/admin/images/file/20141110144845.pdf.; Zhao L., Bai C., Chao Y. et al. A phase II study of neoadjuvant chemoradiotherapy with oxaliplatin and capecitabine for rectal cancer. Cancer Lett 2011;310(2):134–9. Available at: https://www.sciencedirect.com/science/article/pii/S0304383511003715.; Wang J.-P., Вing W.X., Deng Y.H. et al. Preoperative chemoradiotherapy with FOLFOX in low rectal cancer: a multicenter study. Zhonghua Wei Chang Wai Ke Za Zhi Chin J Gastrointest Surg 2008;11(2):116–9. Available at: https://europepmc.org/article/med/18344075.; Allegra C.J., Yothers G., O’Connell M. et al. Neoadjuvant 5-FU or capecitabine plus radiation with or without oxaliplatin in rectal cancer patients: A Phase III Randomized Clinical Trial. J Natl Cancer Inst 2015;107(11). Available at: https://academic.oup.com/jnci/article/107/11/djv248/2457689.; Rödel C., Graeven U., Fietkau R. et al. Oxaliplatin added to fluorouracil-based preoperative chemoradiotherapy and postoperative chemotherapy of locally advanced rectal cancer (the German CAO/ARO/AIO-04 study): final results of the multicentre, open-label, randomised, phase 3 trial. Lancet Oncol 2015;16(8):979–89. Available at: https://www.sciencedirect.com/science/article/pii/S147020451500159X.; Zheng J., Feng X., Huet W. et al. Systematic review and meta-analysis of preoperative chemoradiotherapy with or without oxaliplatin in locally advanced rectal cancer. Medicine (Baltimore) 2017;96(13):e6487. DOI:10.1097/MD.0000000000006487. Available at: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5380275/.; De Felice F., Benevento I., Magnante A. et al. Clinical benefit of adding oxaliplatin to standard neoadjuvant chemoradiotherapy in locally advanced rectal cancer: a meta-analysis: Oxaliplatin in neoadjuvant treatment for rectal cancer. BMC Cancer 2017;17(1):325. Available at: https://bmccancer.biomedcentral.com/articles/10.1186/s12885-017-3323-4.; Tournigand C., Andre T., Achille E. et al. FOLFIRI followed by FOLFOX6 or the re verse sequence in advanced colorec tal cancer: a randomized GERCOR study. J Clin Oncol Off J Am Soc Clin Oncol 2004;22(2):229–37. Available at: http://mauriciolema.webhost4life.com/rolmm/files/GERCOR.pdf.; Klautke G., Küchenmeister U., Foitziket T. al. Concurrent chemoradiation with capecitabine and weekly irinotecan as preoperative treatment for rectal cancer: results from a phase I/II study. Br J Cancer 2006;94(7):976–81. Available at: https://www.nature.com/articles/6603053.; Jung M., Shin S., Koom W. et al. A randomized phase 2 study of neoadjuvant chemoradiaton therapy with 5-fluorouracil/leucovorin or irinotecan/S-1 in patients with locally advanced rectal cancer. Int J Radiat Oncol Biol Phys 2015;93(5):1015–22. Available at: https://www.sciencedirect.com/science/article/pii/S0360301615031946.; DeVita, Hellman, and Rosenberg’s Cancer: Principles & Practice of Oncology. 10 th edn. Philadelphia: LWW, 2014. 2280 p.; Wong S.J., Moughan J., Meropol N. et al. Efficacy endpoints of radiation therapy group protocol 0247: a randomized, phase 2 study of neoadjuvant radiation therapy plus concurrent capecitabine and irinotecan or capecitabine and oxaliplatin for patients with locally advanced rectal cancer. Int J Radiat Oncol Biol Phys 2015;91(1):116–23. Available at: https://www.sciencedirect.com/science/article/pii/S0360301614041807.; Horisberger K., Treschl A., Mai S. et al. Cetuximab in combination with capecitabine, irinotecan, and radiotherapy for patients with locally advanced rectal cancer: results of a Phase II MARGIT trial. Int J Radiat Oncol Biol Phys 2009; 74(5):1487–93. DOI:10.1016/j.ijrobp.2008.10.014. Available at: https://www.sciencedirect.com/science/article/pii/S0360301608035906.; Eisterer W., de Vries A., Ofner D. et al. Preoperative treatment with capecitabine, cetuximab and radiotherapy for primary locally advanced rectal cancer – a phase II clinical trial. Anticancer Res 2014;34(11): 6767–73. Available at: http://ar.iiarjournals.org/content/34/11/6767.short.; Rödel C., Arnold D., Hippet M. al. Phase I–II trial of cetuximab, capecitabine, oxaliplatin, and radiotherapy as preopera tive treatment in rectal cancer. Int J Radiat Oncol Biol Phys 2008;70(4):1081–6. Available at: https://www.sciencedirect.com/science/article/pii/S0360301607037790.; De Felice F., Izzo L., Musio D. et al. Clinical predictive factors of pathologic complete response in locally advanced rectal cancer. Oncotarget 2016;7(22):33374–80. Available at: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5078102/.; Kripp M., Horisberger K., Mai S. et al. Does the addition of cetuximab to radiochemotherapy improve outcome of patients with locally advanced rectal cancer? Long-term results from phase II trials. Gastroenterol Res Pract 2015;2015:273489. DOI:10.1155/2015/273489. Available at: https://www.hindawi.com/journals/grp/2015/273489/.; Benevento I., De Felice F., Musio D., Tombolini V. The addition of target therapy to neoadjuvant chemoradiotherapy in locally advanced rectal cancer: a review. Chemotherapy 2017;62(5):314–22. Available at: https://www.karger.com/Article/Abstract/476056.; Pinto C., Fabio F., Maiello E. et al. Phase II study of panitumumab, oxaliplatin, 5-fluorouracil, and concurrent radiotherapy as preoperative treatment in high-risk locally advanced rectal cancer patients (StarPan/STAR-02 Study). Ann Oncol Off J Eur Soc Med Oncol 2011;22(11):2424–30. Available at: https://www.sciencedirect.com/science/article/pii/S0923753419377117.; Mardjuadi F.I., Carrasco J., Coche J. et al. Panitumumab as a radiosensitizing agent in KRAS wild-type locally advanced rectal cancer. Target Oncol 2015;10(3):375–83. Available at: https://link.springer.com/article/10.1007/s11523-014-0342-9.; Helbling D., Bodoky G., Gautschi O. et al. Neoadjuvant chemoradiotherapy with or without panitumumab in patients with wild-type KRAS, locally advanced rectal cancer (LARC): a randomized, multicenter, phase II trial SAKK 41/07. Ann Oncol Off J Eur Soc Med Oncol 2013;24(3):718–25. Available at: https://www.sciencedirect.com/science/article/pii/S0923753419371455.; Overgaard J., Horsman M. Modification of hypoxia-induced radioresistance in tumors by the use of oxygen and sensitizers. Semin Radiat Oncol 1996;6(1):10–21. Available at: https://www.sciencedirect.com/science/article/pii/S1053429696800324.; Hamming L.C., Slotman B., Verheyul H. et al. The clinical application of angiostatic therapy in combination with radiotherapy: past, present, future. Angiogenesis 2017;20(2):217–32. Available at: https://link.springer.com/content/pdf/10.1007/s10456-017-9546-9.pdf.; Dings R.P.M., Loren M., Heun H. et al. Scheduling of radiation with angiogenesis inhibitors anginex and avastin improves therapeutic outcome via vessel normalization. Clin Cancer Res Off J Am Assoc Cancer Res 2007;13(11):3395–402. DOI:10.1158/1078-0432.CCR-06-2441. Available at: https://clincancerres.aacrjournals.org/content/13/11/3395.short.; Lee C.G., Heijn M., di Tomaso E. et al. Anti-vascular endothelial growth factor treatment augments tumor radiation response under normoxic or hypoxic conditions. Cancer Res 2000;60(19):5565–70. Available at: https://cancerres.aacrjournals.org/content/60/19/5565.short.; Willett C.G., Boucher E., di Tomaso E. et al. Direct evidence that the VEGF-specific antibody bevacizumab has antivascular effects in human rectal cancer. Nat Med 2004;10(2):145–7. Available at: https://www.nature.com/articles/nm988.; Kleibeuker E.A., Fokas E., Allen P. et al. Low dose angiostatic treatment counteracts radiotherapy-induced tumor perfusion and enhances the anti-tumor effect. Oncotarget 2016;7(47):76613–27. Available at: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5363534/.; Winkler F., Kozin S., Tong R. et al. Kinetics of vascular normalization by VEGFR2 blockade governs brain tumor response to radiation: role of oxygenation, angiopoietin-1, and matrix metalloproteinases. Cancer Cell 2004;6(6):553–63. Available at: https://www.sciencedirect.com/science/article/pii/S1535610804003058.; Jain R.K. Molecular regulation of vessel maturation. Nat Med 2003;9(6):685–93. Available at: https://www.nature.com/articles/nm0603-685.; Jain R.K. Normalization of tumor vasculature: an emerging concept in antiangiogenic therapy. Science 2005;307(5706): 58–62. Available at: https://science.sciencemag.org/content/307/5706/58.abstract.; Mayr N.A., Yuh W., Magnotta V. et al. Tumor perfusion studies using fast magnetic resonance imaging technique in advanced cervical cancer: a new noninvasive predictive assay. Int J Radiat Oncol Biol Phys 1996;36(3):623–33. Available at: https://www.sciencedirect.com/science/article/pii/S0360301697850900.; Shibuya K., Tsushima Y., Horisoko E. et al. Blood flow change quantification in cervical cancer before and during radiation therapy using perfusion CT. J Radiat Res (Tokyo) 2011;52(6):804–11. Available at: https://www.jstage.jst.go.jp/article/jrr/52/6/52_11079/article/-char/ja/.; Janssen M.H.M., Aerts H., Kerkelset R. et al. Tumor perfusion increases during hypofractionated short-course radiotherapy in rectal cancer: sequential perfusion-CT findings. Radiother Oncol J Eur Soc Ther Radiol Oncol 2010;94(2):156–60. Available at: https://www.sciencedirect.com/science/article/pii/S0167814009006719.; Borg C., Andre T., Mantion G. et al. Pathological response and safety of two neoadjuvant strategies with bevacizumab in MRI-defined locally advanced T3 resectable rectal cancer: a randomized, noncomparative phase II study. Ann Oncol Off J Eur Soc Med Oncol 2014;25(11):2205–10. Available at: https://www.sciencedirect.com/science/article/pii/S0923753419367717.; Salazar R., Capdevila J., Laquente B. et al. A randomized phase II study of capecitabine-based chemoradiation with or without bevacizumab in resectable locally advanced rectal cancer: clinical and biological features. BMC Cancer 2015;(15):60. Available at: https://bmccancer.biomedcentral.com/articles/10.1186/s12885-015-1053-z.; Dellas K., Höhler T., Reese T. et al. Phase II trial of preoperative radiochemotherapy with concurrent bevacizumab, capecitabine and oxaliplatin in patients with locally advanced rectal cancer. Radiat Oncol Lond Engl 2013;(8):90. Available at: https://link.springer.com/article/10.1186/1748-717X-8-90.; Landry J.C., Feng Y., Prabhu R. et al. Phase II trial of preoperative radiation with concurrent capecitabine, oxaliplatin, and bevacizumab followed by surgery and postoperative 5-fluorouracil, leucovorin, oxaliplatin (FOLFOX), and bevacizumab in patients with locally advanced rectal cancer: 5-year clinical outcomes ECOG-ACRIN Cancer Research Group E3204. The Oncologist 2015;20(6):615–6. DOI:10.1634/theoncologist.2015-0106. Available at: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4571787/.; Kennecke H., Berry S., Wong R. et al. Pre-operative bevacizumab, capecitabine, oxaliplatin and radiation among patients with locally advanced or low rectal cancer: a phase II trial. Eur J Cancer Oxf Engl 2012;48(1):37–45. Available at: https://www.sciencedirect.com/science/article/pii/S0959804911003492.; Spigel D.R., Bendell J., McCleod M. et al. Phase II study of bevacizumab and chemoradiation in the preoperative or adjuvant treatment of patients with stage II/III rectal cancer. Clin Colorectal Cancer 2012;11(1):45–52. Available at: https://www.sciencedirect.com/science/article/pii/S1533002811000338.; Resch G., de Vries A., Ofner D. et al. Preoperative treatment with capecitabine, bevacizumab and radiotherapy for primary locally advanced rectal cancer – a two stage phase II clinical trial. Radiother Oncol J Eur Soc Ther Radiol Oncol 2012;102(1):10–3. Available at: https://www.sciencedirect.com/science/article/pii/S0167814011003197.; Czito B.G., Yu D., Mantyh Ch. et al. Increased toxicity with gefitinib, capecitabine, and radiation therapy in pancreatic and rectal cancer: phase I trial results. J Clin Oncol Off J Am Soc Clin Oncol 2006;24(4):656–62. Available at: https://www.researchgate.net/profile/Christopher_Mantyh/publication/7328246_Increased_Toxicity_With_Gefitinib_Capecitabine_and_Radiation_Therapy_in_Pancreatic_and_Rectal_Cancer_Phase_I_Trial_Results/links/00463533d73eed512c000000/Increased-Toxicity-With-Gefitinib-Capecitabine-and-Radiation-Therapy-in-Pancreatic-and-Rectal-Cancer-Phase-I-Trial-Results.pdf.; Chiang S.-F., Chuang C., Ke T.-W. et al. Upregulation of tumor PD-L1 by neoadjuvant chemoradiotherapy (neoCRT) confers improved survival in patients with lymph node metastasis of locally advanced rectal cancers. Cancer Immunol Immunother 2019;68(2):283–96. Available at: https://link.springer.com/article/10.1007/s00262-018-2275-0.; Rödel C., Hofheinz R., Fokas E. Rectal cancer: Neoadjuvant chemoradiotherapy. Best Pract Res Clin Gastroenterol 2016;30(4):629–39. Available at: https://www.sciencedirect.com/science/article/pii/S1521691816300440.; Fernandez-Martos C. Chemoradiation, surgery and adjuvant chemotherapy versus induction chemotherapy followed by chemoradiation and surgery: long-term results of the Spanish GCR-3 phase II randomized trial. Ann Oncol 2015;26(8):1722–8. Available at: https://www.sciencedirect.com/science/article/pii/S0923753419318514.; Cercek A., Goodman K. Neoadjuvant chemotherapy first, followed by chemoradiation and then surgery, in the management of locally advanced rectal cancer. J Natl Compr Cancer Netw JNCCN 2014; 12(4):513–9. Available at: https://jnccn.org/view/journals/jnccn/12/4/article-p513.xml.; Glynne-Jones R., Chau I. Neoadjuvant therapy before surgical treatment. EJC Suppl 2013;11(2):45–59. Available at: https://www.sciencedirect.com/science/article/pii/S1359634913000335.; Habr-Gama A., Perez R.O., Nadalin V. et al. Operative versus nonoperative treatment for stage 0 distal rectal cancer following chemoradiation therapy: long-term results. Ann Surg 2004;240(4):711–7; discussion 717–8. DOI:10.1097/01.sla.0000141194.27992.32. Available at: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC1356472/.; Martens M.H., Maas M., Heijnen L.A. et al. Long-term outcome of an organ preservation program after neoadjuvant treatment for rectal cancer. JNCI J Natl Cancer Inst Oxford Academic 2016;108(12): 171. DOI:10.1093/jnci/djw171. Available at: https://academic.oup.com/jnci/article/108/12/djw171/2706932.
-
5Academic Journal
Συγγραφείς: D. V. Kuzmichev, Z. Z. Mamedli, A. V. Polynovskiy, Zh. M. Madyarov, S. I. Tkachev, А. A. Aniskin, Д. В. Кузьмичев, З. З. Мамедли, А. В. Полыновский, Ж. М. Мадьяров, С. И. Ткачев, А. А. Анискин
Πηγή: Surgery and Oncology; Том 8, № 3 (2018); 36-41 ; Хирургия и онкология; Том 8, № 3 (2018); 36-41 ; 2949-5857 ; 10.17650/2220-3478-2018-8-3
Θεματικοί όροι: патоморфоз, chemoradiotherapy, neoadjuvant chemotherapy, consolidation chemotherapy, induction chemotherapy, “sandwich” therapy, pathomorphosis, химиолучевая терапия, неоадъювантная химиотерапия, консолидирующая химиотерапия, индукционная химиотерапия, «sandwich»-терапия
Περιγραφή αρχείου: application/pdf
Relation: https://www.onco-surgery.info/jour/article/view/258/218; Давыдов М. И., Аксель Е. М. Статистика злокачественных новообразований в России и странах СНГ в 2009 г. Вестник РОНЦ им. Н. Н. Блохина РАМН 2011;22(3 прил. 1).; National Comprehensive Cancer Network Clinical Practice Guidelines in Oncology. Rectal Cancer(v. 3, 2017). Available at: https://www.nccn.org/professionals/physician_gls/pdf/rectal.pdf.; Glynne-Jones R., Wyrwicz L., Tiret E. et al. Rectal cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol 2017;28(Suppl 4):iv22–40. PMID: 28881920. DOI:10.1093/annonc/mdx224.; Клинические рекомендации «Рак прямой кишки» от 2017 г. Доступно по: http://oncology-association.ru/ files/clinicalguidelines_adults/rak_ pryamoy_kishki.pdf.; Berardi R., Maccaroni E., Onofri A. et al. Multidisciplinary treatment of locally advanced rectal cancer: a literature review. Part 1. Expert Opin Pharmacother 2009;10(14):2245–58. PMID: 19640208. DOI:10.1517/14656560903143776.; Benson A. B., Bekaii-Saab T., Chan E. et al. Rectal cancer. J Natl Compr Cancer Netw 2012;10(12):1528–64. PMID: 23221790.; Lee M., Gibbs P., Wong R. Multidisciplina ry management of locally advanced rectal cancer – an evolving landscape? Clin Colorectal Cancer 2015;14(4):251–61. PMID: 26210575. DOI:10.1016/j.clcc.2015.06.002.; Smith J. J., Garcia-Aguilar J. Advances and challenges in treatment of locally advanced rectal cancer. J Clin Oncol 2015;33(16):1797–808. PMID: 25918296. DOI:10.1200/JCO.2014.60.1054.; Sauer R., Becker H., Hohenberger W. et al. Preoperative versus postoperative chemoradiotherapy for rectal cancer. N Engl J Med 2004;351(17):1731–40. PMID: 15496622. DOI:10.1056/NEJMoa040694.; Cercek A., Roxburgh C. S.D., Strombom P. et al. Adoption of Total Neoadjuvant Therapy for Locally Advanced Rectal Cancer. JAMA Oncol 2018;4(6):e180071. DOI:10.1001/jamaoncol.2018.0071.; Dewdney A., Cunningham D., Tabernero J. et al. Multicenter randomized phase II clinical trial comparing neoadjuvant oxaliplatin, capecitabine, and preoperative radiotherapy with or without cetuximab followed by total mesorectal excision in patients with high-risk cancer (EXPERT-C). J Clin Oncol 2012;30:1620–7.; Chua Y. J., Barbachano Y., Cunningham D. et al. Neoadjuvant capecitabine and oxaliplatin before chemoradiotherapy and total mesorectal excision in MRI-defined poor-risk rectal cancer: a phase 2 trial. Lancet Oncol 2010;11:241–8.; Schou J. V., Larsen F. O., Rasch L. et al. Induction chemotherapy with capecitabine and oxaliplatin followed by chemoradiotherapy before total mesorectal excision in patients with locally advanced rectal cancer. Ann Oncol 2012;23(10):2627–33. PMID: 22473488. DOI:10.1093/annonc/mds056.; Bujko K., Wyrwicz L., Rutkowski A. et al. Long-course oxaliplatin-based preoperative chemoradiation versus 5 × 5 Gy and consolidation chemotherapy for cT4 or fixed cT3 rectal cancer: results of a randomized phase III study. Ann Oncol 2016;27(5):834–42. PMID: 26884592. DOI:10.1093/annonc/mdw062.; Schrag D. PROSPECT: Chemotherapy alone/chemotherapy plus radiation therapy in treating patients with locally advanced rectal cancer undergoing surgery. Available at: https://clinicaltrials.gov/ct2/show/NCT01515787.; Taylor F. G., Quirke P., Heald R. J. et al. Preoperative high-resolution magnetic resonance imaging can identify good prognosis stage I, II, and III rectal cancer best managed by surgery alone: a prospective, multicenter, European study. Ann Surg 2011;253:711–9.; Bhoday J., Balyasnikova S., Wale A., Brown G. How Should Imaging Direct/ Orient Management of Rectal Cancer? Clin Colon Rectal Surg 2017;30(5):297– 312. DOI:10.1055/s-0037-1606107.; Habr-Gama A., Perez R. O., Sabbaga J. et al. Increasing the rates of complete response to neoadjuvant chemoradiotherapy for distal rectal cancer: results of a prospective study using additional chemotherapy during the resting period. Dis Colon Rectum 2009;52:1927–34.; Xiao J., Chen Z., Li W. et al. Sandwichlike neoadjuvant therapy with bevacizumab for locally advanced rectal cancer: a phase II trial. Cancer Chemother Pharmacol 2015;76(1):21–7. DOI:10.1007/s00280-015-2763-2.; Лавникова Г. А. Гистологический метод количественной оценки терапевтического повреждения опухоли. М.: Методические рекомендации, 1979. 13 с.; Medical Research Council Rectal Cancer Working Party. Randomised trial of surgery alone versus radiotherapy followed by surgery for potentially operable locally advanced rectal cancer. Lancet 1996;48(9042):1605–10.; Wong R. K., Tandan V., De Silva S., Figueredo A. Pre-operative radiotherapy and curative surgery for the management of localized rectal carcinoma. Cochrane Database Syst Rev 2007;(2):CD002102. PMID: 17443515. DOI:10.1002/14651858.CD002102.pub2.; McCarthy K., Pearson K., Fulton R. et al. Pre-operative chemoradiation for nonmetastatic locally advanced rectal cancer. Cochrane Database Syst Rev 2012;(12): CD008368. PMID: 23235660. DOI:10.1002/14651858.CD008368.pub2.; Bosset J. F., Collette L. Calais G. et al. Chemotherapy with preoperative radiotherapy in rectal cancer. N Engl J Med 2006;355(11):1114–23. PMID: 16971718. DOI:10.1056/NEJMoa060829.; Land S. R., Ritter M. W., Costantino J. P. et al. Compliance with patient-reported outcomes in multicenter clinical trials: methodologic and practical approaches. J Clin Oncol 2007;25(32):5113–20. PMID: 17991930. DOI:10.1200/JCO.2007.12.1749.; Fernandez-Martos C., Pericay C., Aparicio J. et al. Phase II, randomized study of concomitant chemoradiotherapy followed by surgery and adjuvant capecitabine plus oxaliplatin (CAPOX) compared with induction CAPOX followed by concomitant chemoradiotherapy and surgery in magnetic resonance imaging-defined, locally advanced rectal cancer: Grupo cancer de recto 3 study. J Clin Oncol 2010;28(5):859–65. DOI:10.1200/JCO.2009.25.8541.; Gerard J. P., Conroy T., Bonnetain F. et al. Preoperative radiotherapy with or without concurrent fluorouracil and leucovorin in T3–4 rectal cancers: results of FFCD 9203. J Clin Oncol 2006;24(28):4620–5. PMID: 17008704. DOI:10.1200/JCO.2006.06.7629ю; Chau I., Brown G., Cunningham D. et al. Neoadjuvant capecitabine and oxaliplatin followed by synchronous chemoradiation and total mesorectal excision in magnetic resonance imaging-defined poor-risk rectal cancer. J Clin Oncol 2006;24:668–74. PMID: 16446339. DOI:10.1200/JCO.2005.04.4875.; Perez K., Pricolo V., Vrees M. et al. A phase II study of complete neoadjuvant therapy in rectal cancer (CONTRE): The Brown University Oncology Group. J Clin Oncol 2013;31: abstr 335. DOI:10.1200/jco.2013.31.4_suppl.335.; Gao Y. H., Zhang X., An X. et al. Oxaliplatin and capecitabine concomitant with neoadjuvant radiotherapy and extended to the resting period in high risk locally advanced rectal cancer. Strahlen ther Onkol 2014;19092):158–64. PMID: 24408055. DOI:10.1007/s00066-013-0500-5.; Gao Y. H., Lin J. Z., An X. et al. Neoadjuvant sandwich treatment with oxaliplatin and capecitabine administered prior to, concurrently with, and following radiation therapy in locally advanced rectal cancer: a prospective phase 2 trial. Int J Radiat Oncol Biol Phys 2014;90(5):1153–60. DOI:10.1016/j.ijrobp.2014.07.021.
-
6Academic Journal
Συγγραφείς: A. O. Rasulov, Z. Z. Mamedli, D. V. Kuz’michev, D. H. Khudoerov, N. A. Kozlov, Yu. E. Suraeva, S. S. Balyasnikova, А. О. Расулов, З. З. Мамедли, Д. В. Кузьмичев, Д. Х. Худоеров, Н. А. Козлов, Ю. Э. Сураева, С. С. Балясникова
Πηγή: Surgery and Oncology; Том 6, № 4 (2016); 13-17 ; Хирургия и онкология; Том 6, № 4 (2016); 13-17 ; 2949-5857 ; 10.17650/2220-3478-2016-6-4
Θεματικοί όροι: трансанальная эндоскопическая микрохирургия, neoadjuvant chemoradiotherapy, consolidation chemotherapy, complete clinical response, transanal endoscopic microsurgery, неоадъювантная химиолучевая терапия, консолидирующая химиотерапия, полный клинический ответ
Περιγραφή αρχείου: application/pdf
Relation: https://www.onco-surgery.info/jour/article/view/186/160; McCarthy K., Pearson K., Fulton R., Hewitt J. Pre-operative chemoradiation for non-metastatic locally advanced rectal cancer. Cochrane Database Syst Rev 2012;12:CD008368. DOI:10.1002/14651858.CD008368.pub2.; Gerard A., Buyse M., Nordlinger B. et al. Preoperative radiotherapy as adjuvant treatment in rectal cancer: final results of a randomised study of the European Organisation for Research and Treatment of Cancer (EORTC). Ann Surg 1988;208(5):606–14.; Minsky B.D., Cohen A.M., Kemeny N. et al. Efficacy of preoperative 5-FU, high dose leucovorin, and sequential radiation therapy for unresectable rectal cancer. Cancer 1993;71(1):3486–92.; Chen E.T., Mohiuddin M., Brodovsky H. et al. Downstaging of advanced rectal cancer following combined preoperative chemotherapy and high dose radiation. Int J Radiat Oncol Biol Phys 1994;30:169–75.; Renehan A.G., Malcomson L., Emsley R. et al. Watch-and-wait approach versus surgical resection after chemoradiotherapy for patients with rectal cancer (the OnCoRe project): a propensity-score matched cohort analysis. Lancet Oncol 2016;17(2):174–83. DOI:10.1016/S1470-2045(15)00467-2.; Paun B.C., Cassie S., MacLean A.R. et al. Postoperative complications following surgery for rectal cancer. Ann Surg 2010;251(5):807–18. DOI:10.1097/SLA.0b013e3181dae4ed.; Ferrari L., Fichera A., Neoadjuvant chemoradiation therapy and pathological complete response in rectal cancer. Gastroenterol Rep 2015;3(4):277–88. DOI:10.1093/gastro/gov039.; Habr-Gama A., Perez R.O., Nadalin W. et al. Operative versus nonoperative treatment for stage 0 distal rectal cancer following chemoradiation therapy: long-term results. Ann Surg 2004;240(4):711–7.; Patel U.B., Blomgvist L.K., Taylor F. et al. MRI after treatment of locally advanced rectal cancer: how to report tumor responsethe MERCURY experience. AJR Am J Roentgenol 2012;199(4):W486–95.; Rutten H., Glynne-Jones D.S.-M., Rullier E. et al. Capecitabine, oxaliplatin, radiotherapy, and excision (CORE) in patients with MRI-defined locally advanced rectal adenocarcinoma: Results of an international multicenter phase II study. J Clin Oncol 2006;(Suppl; abstr 3528): 24(153s).; Maas M., Beets-Tan R.G., Lambregts D.M. et al. Wait-and-see policy for clinical complete responders after chemoradiation for rectal cancer. Clin Oncol 2011;29(35):4633–40.; Habr-Gama A., Perez R.O., Proscurshim I. et al. Patterns of failure and survival for non-operative treatment of stage c0 distal rectal cancer following neoadjuvant chemoradiation therapy. J Gastrointest Surg 2006;10:1319–29.; Habr-Gama A., Gama-Rodrigues J., Sao Juliano G.P. et al. Local recurrence after complete clinical response and watch and wait in rectal cancer after neoadjuvant chemoradiation: impact of salvage therapy on local disease control. Int J Radiat Oncol Biol Phys 2014;88(4):822–8. DOI:10.1016/j.ijrobp.2013.12.012.; Patel U.B., Taylor F., Blomqvist L. et al. Magnetic resonance imaging-detected tumor response for locally advanced rectal cancer predicts survival outcomes: MERCURY experience. J Clin Oncol 2011;29(28):3753–60. DOI:10.1200/JCO.2011.34.9068.; Dresen R.C., Beets G.L., Rutten H.J. et al. Locally advanced rectal cancer: MR imaging for restaging after neoadjuvant radiation therapy with concomitant chemotherapy. Part I. Are we able to predict tumour confined to the rectal wall? Radiology 2009;252(1):71–80. DOI:10.1148/radiol.2521081200.; Smith F.M., Waldron D., Winter D.C. Rectum-conserving surgery in the era of chemoradiotherapy. Br J Surg 2010; 97(12):1752–64. DOI:10.1002/bjs.7251.; Balyasnikova S., Bhoday J., Siddiqui M. et al. Is there any added value of DWI, mrVolumetric regression and mrRECIST analyses against mrTRG in finding patients with maintained complete response for deferral of surgery trial approach? ESCP, 2016;(Abstr 0711).; Smith F.M., Brown G., Heald R.J. et al. O’Neill B.D., Brown G et al. Non-operative treatment after neoadjuvant chemoradiotherapy for rectal cancer. Lancet Oncol 2007;8(7):625–33.; Maas M., Nelemans P.J., Valentini V. et al. Long-term outcome in patients with a pathologic complete response after chemoradiation for rectal cancer: a pooled analysis of 3105 patients. Lancet Oncol 2011;11:835–44.; Gao Y.H., Zhang X., An X. et al. Oxaliplatin and capecitabine concomitant with neoadjuvant radiotherapy and extended to the resting period in high risk locally advanced rectal cancer. Strahlenther Onkol 2014;90(2):158–64.; Verseveld M., de Graaf E.J., Verhoef C. et al. Chemoradiation therapy for rectal cancer in the distal rectum followed by organ-sparing transanal endoscopic microsurgery (CARTS study). Br J Surg 2015;102(7):853–60.; Garcia-Aguilar J., Renfro L.A., Chow O.S. et al. Organ preservation for clinical T2N0 distal rectal cancer using neoadjuvant chemoradiotherapy and local excision (ACOSOG Z6041): results of an open-label, single-arm, multiinstitutional, phase 2 trial. Lancet Oncol 2015;16(15):1537–46.; Lambregts D.M., Cappendijk V.C., Maas M. et al. Value of MRI and diffusionweighted MRI for the diagnosis of locally recurrent cancer. Eur Radiol 2011;21:1250–8.